Sugi Predict

Sugi Predict / Compounds / SCHEMBL239875

SCHEMBL239875

SCHEMBL239875

COC(=O)N[C@H](C(=O)O)C1CCC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 6/20 0.39
▸ MMP1 P03956 4/20 0.39
▸ MMP3 P08254 4/20 0.39
▸ MMP13 P45452 4/20 0.39
▸ MMP7 P09237 2/20 0.39
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ PYGL P06737 5/20 0.35
▸ AAK1 Q2M2I8 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ THRB P10828 1/20 0.34
▸ CYP2C9 P11712 2/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP14 P50281 1/20 0.33
▸ BTK Q06187 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27923509 1.00 MMP2 (0.39) MMP2MMP1MMP3MMP13MMP7
SCHEMBL1804269 0.96 MMP2 (0.42) MMP2MMP1MMP3MMP13MMP7
SCHEMBL240589 0.96 MMP2 (0.42) MMP2MMP1MMP3MMP13MMP7
SCHEMBL241407 0.94 MMP2 (0.44) MMP2MMP1MMP3MMP13MMP7
SCHEMBL204610 0.94 MMP2 (0.44) MMP2MMP1MMP3MMP13MMP7
SCHEMBL6435900 0.94 MMP2 (0.44) MMP2MMP1MMP3MMP13MMP7
SCHEMBL193724 0.92 MMP2 (0.37) MMP2MMP1MMP3MMP13MMP7
SCHEMBL206034 0.92 MMP2 (0.37) MMP2MMP1MMP3MMP13MMP7
SCHEMBL5988923 0.85 MMP2 (0.36) MMP2MMP1MMP3MMP13MMP7
SCHEMBL12147599 0.85 MMP2 (0.36) MMP2MMP1MMP3MMP13MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US disclosed
EP-2499127-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-05 — — EP disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 — — US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 — — US disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
US-9776981-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-03 — — US disclosed
CN-106986861-A Antiviral compound 艾伯维巴哈马有限公司 2017-07-28 — — CN disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
EP-2499127-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 — — EP disclosed
EP-2499115-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 — — EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 — — US disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
US-20110274648-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-11-10 — — US disclosed
US-20110269956-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-11-03 — — US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
WO-2011059887-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 — — WO disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR HAVCR2, LIPC, PYGL MMP2 1291/4885MMP1 4033/4885MMP3 2946/4885
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110269956-A1 Hepatitis C Virus Inhibitors HAVCR2, HCCS, MAVS MMP2 1410/4885MMP1 4001/4885MMP3 2369/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885
US-20110274648-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS MMP2 1142/4885MMP1 3898/4885MMP3 2742/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS MMP2 2627/4885MMP1 3845/4885MMP3 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.